The PROVID randomized clinical trial demonstrates a 93.8% posterior probability that awake prone positioning (APP) reduces the composite risk of intubation and death in COVID-19 patients.
Optimal efficacy is associated with a target duration of at least 6 hours per day, though adherence remains a significant clinical challenge.
APP improves oxygenation through enhanced ventilation-perfusion matching and more homogeneous distribution of pleural pressure, potentially preventing self-inflicted lung injury (P-SILI).
Integration of Bayesian statistical models in recent trials provides a more nuanced understanding of therapeutic benefit compared to traditional frequentist approaches.
